Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
1Q19 Galafold® (migalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19 Galafold Revenue of $34.0M and Early 2Q19 Momentum on Key Launch Metrics Maintaining …